U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07836101) titled 'Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events' on Sept. 17.
Brief Summary: The study will enroll patients with history of malignancy treated with immune checkpoint inhibitors (ICI) that have developed a grade 2 or higher immune related adverse event requiring treatment discontinuation as deemed by the patient's treating physician. Patients will be sequentially enrolled into the single-arm study after meeting the pre-specified eligibility criteria
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Any Advanced Solid Tumors
In...